SEC Form 4 · accession 0001123292-16-002319

Recro Pharma, Inc. · REPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Wayne Weisman

Director

Period of report

Nov 23, 2015

Accepted (ET)

May 23, 2016 · 6:04 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001588972

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Nov 23, 2015	S	11,082	$9.0009	D	2,362,964	I	By SCP Vitalife Partners II LP
Common Stock^F1	Nov 23, 2015	S	3,702	$9.0009	D	789,538	I	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock^F2	Nov 24, 2015	S	2,068	$9.006	D	2,360,896	I	By SCP Vitalife Partners II LP
Common Stock^F2	Nov 24, 2015	S	691	$9.006	D	788,847	I	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock	Nov 25, 2015	S	4,648	$9.00	D	2,356,248	I	By SCP Vitalife Partners II LP
Common Stock	Nov 25, 2015	S	1,553	$9.00	D	787,294	I	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock^F3	Nov 27, 2015	S	6,737	$9.0009	D	2,349,511	I	By SCP Vitalife Partners II LP
Common Stock^F3	Nov 27, 2015	S	2,250	$9.0009	D	785,044	I	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock	Nov 30, 2015	S	450	$9.00	D	2,349,061	I	By SCP Vitalife Partners II, L.P.
Common Stock	Nov 30, 2015	S	150	$9.00	D	784,894	I	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock^F4	May 19, 2016	S	3,748	$6.4559	D	2,345,313	I	By SCP Vitalife Partners II LP
Common Stock^F4	May 19, 2016	S	1,252	$6.4559	D	783,642	I	By SCP Vitalife Partners (Israel) II, L.P.
Common Stock^F5	May 20, 2016	S	14,992	$6.4548	D	2,330,321	I	By SCP Vitalife Partners II LP
Common Stock^F5	May 20, 2016	S	5,008	$6.4548	D	778,634	I	By SCP Vitalife Partners (Israel) II, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.05, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.07, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.59, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.58, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 5 to this Form 4.